Zymeworks grabs Theravance in $929 million respiratory buyout
Zymeworks has closed its $929 million takeover of Theravance Biopharma, picking up a commercial COPD drug and a set of royalty streams that reshape its revenue mix.
Jazz Pharmaceuticals 1 article
Jazz Pharmaceuticals is a biopharmaceutical company characterized by sleep disorder therapeutics and epilepsy therapeutics; its scientific profile also incorporates hematology oncology therapeutics. Jazz Pharmaceuticals links hematology oncology therapeutics, neuroscience medicines and narcolepsy treatment development; this combination gives Jazz Pharmaceuticals a defined disease and mechanistic context. The taxonomy keeps Jazz Pharmaceuticals at the organization layer and treats cannabinoid-derived seizure medicines as supporting scientific context rather than an alternate entity name.